OR
Oruka Therapeutics, Inc.
ORKA · NASDAQ
$93.38 -1.90% (-$1.81)
1M -7.28%
Market Cap $5.90B
P/E Ratio -
Div. Yield -
ROE 20.76%
Piotroski F-Score Weak
2/9Valuation
34 /100
Fair P/B 5.29x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 13.88%
ROE 20.76%
ROA 11.66%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 38.51x
Int. coverage N/A
Stability
50 /100
Moderate Beta -0.39x
Rev. volatility N/A
EPS volatility N/A
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ORKA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Lawrence Otto Klein
Employees
68
Headquarters
Menlo Park
Upcoming events
11 NOV
Earnings
Upcoming earnings report